Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Immunocore Holdings plc, Amphastar Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc.

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Latest Biotechnology and Immunocore Holdings plc, Amphastar Pharmaceuticals, Inc. Stock News

As of July 30, 2026, Immunocore Holdings plc had a $1.7 billion market capitalization, compared to the Biotechnology median of $251.9 million. Immunocore Holdings plc’s stock is down 2.6% in 2026, down 3.4% in the previous five trading days and down 0.12% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $412.8 million with a -6.7% net profit margin. Year-over-year quarterly sales growth most recently was 13.6%. There are no analysts providing consensus earnings estimates for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

As of July 30, 2026, Amphastar Pharmaceuticals, Inc. had a $898.6 million market cap, putting it in the 44th percentile of all stocks. Amphastar Pharmaceuticals, Inc.’s stock is down 25.5% in 2026, up 6.5% in the previous five trading days and down 5.95% in the past year.

Currently, Amphastar Pharmaceuticals, Inc.’s price-earnings ratio is 12.2. Amphastar Pharmaceuticals, Inc.’s trailing 12-month revenue is $720.5 million with a 11.0% net profit margin. Year-over-year quarterly sales growth most recently was 0.4%. Analysts expect adjusted earnings to reach $2.557 per share for the current fiscal year. Amphastar Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
Immunocore Holdings plc	IMCR	D
Amphastar Pharmaceuticals, Inc.	AMPH	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Immunocore Holdings plc has a Growth Score of 26, which is Weak. Amphastar Pharmaceuticals, Inc. has a Growth Score of 83, which is Very Strong.

The Growth Grade Winner: Amphastar Pharmaceuticals, Inc.

As you can clearly see from the Growth Grade breakdown above, Amphastar Pharmaceuticals, Inc. has a more attractive growth grade than Immunocore Holdings plc. For investors who focus solely on how a company is growing relative to other companies in the same industry, Amphastar Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Immunocore Holdings plc	IMCR	D
Amphastar Pharmaceuticals, Inc.	AMPH	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Immunocore Holdings plc has a Quality Score of 30, which is Weak. Amphastar Pharmaceuticals, Inc. has a Quality Score of 83, which is Very Strong.

The Quality Grade Winner: Amphastar Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Amphastar Pharmaceuticals, Inc. has a better overall quality grade than Immunocore Holdings plc. For investors who are looking for companies with higher quality than others in the same industry, Amphastar Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Immunocore Holdings plc	IMCR	C
Amphastar Pharmaceuticals, Inc.	AMPH	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Immunocore Holdings plc has a Earnings Estimate Score of 48, which is Neutral. Amphastar Pharmaceuticals, Inc. has a Earnings Estimate Score of 11, which is Very Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Immunocore Holdings plc, Amphastar Pharmaceuticals or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Immunocore Holdings plc, Amphastar Pharmaceuticals or Inc. is the better investment when it comes to estimate revisions.

Other Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc. Grades

In addition to Quality, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Immunocore Holdings plc, Amphastar Pharmaceuticals or Inc. Stock?

Overall, Immunocore Holdings plc stock has a Growth Score of 26, Estimate Revisions Score of 48 and Quality Score of 30.

Amphastar Pharmaceuticals, Inc. stock has a Growth Score of 83, Estimate Revisions Score of 11 and Quality Score of 83.

Comparing Immunocore Holdings plc, Amphastar Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.